The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.Cette invention concerne des compositions pharmaceutiques comprenant : (a) au moins un bloqueur du récepteur dangiotensine ou sel de qualité pharmaceutique de celui-ci, et (b) au moins un inhibiteur de la voie du récepteur de chimiokines ou sel de qualité pharmaceutique de celui-ci.Cette invention concerne également des compositions pharmaceutiques comprenant : (a) au moins un bloqueur du récepteur dangiotensine ou sel de qualité pharmaceutique de celui-ci, et (b) au moins un inhibiteur de l
